ABSTRACT
@#AIM: To observe the curative effect of excision combined with concavity-convex amniotic membrane transplantation in the treatment of intraepithelial epithelioma.<p>METHODS:Totally 24 cases of intraepithelial neoplasia(24 eye)diagnosed in our department were studied. The tumors of 12 cases were removed and the wound were covered by the concavity-convex amniotic membrane in the conjunctiva and part of the resection, and other 12 were covered by the amniotic membrane. The effect of these two surgeries were assessed via observing the epithelial healing, degradation of biological amnion, tear break-up time, tumor recurrence and other complications. The resection of the tumor were analyzed histopathologically.<p>RESULTS: The pathological results of all the patients were epithelial carcinoma. There were 24 patients that diagnosed -intraepithelial epithelioma pathologically. The conjunctival epithelium healed rapidly and were completed in 5d after operation in both groups. The amniotic membrane was completely degraded in about 14d. Postoperative visual acuity improvement was not statistically significant in two groups. All patients were followed up for more than 1y. The recurrence rates were significantly lower in concavity-convex amniotic membrane group than that in amniotic membrane group. <p>CONCLUSION: Tumor resection combined with concavity-convex amniotic membrane transplantation is an effective operation method for the treatment of intraepithelial epithelioma.
ABSTRACT
OBJECTIVE@#To study the effects of inhibited Annexin A2 (ANXA2) on human umbilical vein endothelial cells (HUVECs) in vitro.@*METHODS@#Short hairpin RNA (shRNA) targeting ANXA2 was designed and cloned into double marked lentivirial vector GV248 for RNAi to generate the recombinant expression plasmids, which were stably transfected into HUVECs. The protein and mRNA expression levels of ANXA2 were analyzed by western blotting and real-time polymerase chain reaction, respectively. Cell proliferation (cell counting kit-8 assay), apoptosis (flow cytometry analysis), the expression (western blotting) and the activity of caspases (enzyme-linked immunosorbent assay) were used to assess the effects of silencing ANXA2 on HUVECs in vitro.@*RESULTS@#The plasmids to express ANXA2-specific shRNA were constructed and were infected into HUVEC resulting in the stably transfected experimental (ANXA2-shRNA), control (control-shRNA) and mock (no plasmid) cell lines, which were verified with western blot and real-time PCR. HUVEC/ANXA2-shRNA showed an inhibition rate 91.89% of ANXA2 expression compared to the mock HUVEC. ANXA2 silencing cell strain obviously presented a lower cell proliferation activity compared to the control and mock HUVECs, with an inhibition rate 82.35% on day 7 in vitro. FACS analysis indicated that the HUVEC/ANXA2-shRNA cells undergoing apoptosis increased by 102.61% compared to the mock HUVECs (P < 0.01). Moreover, the activity levels of caspase-3, caspase-8 and caspase-9 in HUVEC/ANXA2-shRNA cells were increased and the activated cleaved caspase-3, cleaved caspase-8 and cleaved caspase-9 were upregulated evidently compared with that of the control and mock HUVECs by 56.29%, 89.59% and 144.58% (P < 0.01).@*CONCLUSIONS@#shRNA-mediated silencing of ANXA2 could not only be able to suppress HUVECs proliferation but to upregulate the enzyme activity of caspases, which bring to an increase of cell apoptosis. This work suggested that ANXA2 may represent a useful target of future molecular therapies.
ABSTRACT
Objective: To study the effects of inhibited Annexin A2 (ANXA2) on human umbilical vein endothelial cells (HUVECs) in vitro. Methods: Short hairpin RNA (shRNA) targeting ANXA2 was designed and cloned into double marked lentivirial vector GV248 for RNAi to generate the recombinant expression plasmids, which were stably transfected into HUVECs. The protein and mRNA expression levels of ANXA2 were analyzed by western blotting and real-time polymerase chain reaction, respectively. Cell proliferation (cell counting kit-8 assay), apoptosis (flow cytometry analysis), the expression (western blotting) and the activity of caspases (enzyme-linked immunosorbent assay) were used to assess the effects of silencing ANXA2 on HUVECs in vitro. Results: The plasmids to express ANXA2-specific shRNA were constructed and were infected into HUVEC resulting in the stably transfected experimental (ANXA2-shRNA), control (control-shRNA) and mock (no plasmid) cell lines, which were verified with western blot and real-time PCR. HUVEC/ANXA2-shRNA showed an inhibition rate 91.89% of ANXA2 expression compared to the mock HUVEC. ANXA2 silencing cell strain obviously presented a lower cell proliferation activity compared to the control and mock HUVECs, with an inhibition rate 82.35% on day 7 in vitro. FACS analysis indicated that the HUVEC/ANXA2-shRNA cells undergoing apoptosis increased by 102.61% compared to the mock HUVECs (P < 0.01). Moreover, the activity levels of caspase-3, caspase-8 and caspase-9 in HUVEC/ANXA2-shRNA cells were increased and the activated cleaved caspase-3, cleaved caspase-8 and cleaved caspase-9 were upregulated evidently compared with that of the control and mock HUVECs by 56.29%, 89.59% and 144.58% (P < 0.01). Conclusions: shRNA-mediated silencing of ANXA2 could not only be able to suppress HUVECs proliferation but to upregulate the enzyme activity of caspases, which bring to an increase of cell apoptosis. This work suggested that ANXA2 may represent a useful target of future molecular therapies.
ABSTRACT
<p><b>OBJECTIVE</b>To investigate the application of partial costectomy and costophrenic angle closure (PCCAC) and perioperative management in the treatment of liver tumor by high intensity focused ultrasound (HIFU).</p><p><b>METHODS</b>The clinical data of 69 patients with liver tumor underwent HIFU within the recent four years were retrospectively reviewed.</p><p><b>RESULTS</b>92.8% of these 69 liver tumor patients had had concomitant diseases and 13.0% of them developed postoperative complications without anyone died. There was no significant postoperative dysfunctions of kidney or lung as compared with the preoperative ones (P > 0.05).</p><p><b>CONCLUSION</b>In the treatment of liver tumor by HIFU, PCCAC, as an auxillary means, giving few complications and little harmful effects on respiratory physiology, is highly safe.</p>